The global plasma derived therapy market has demonstrated steady expansion, reflecting its critical role in treating rare and chronic conditions. The market was valued at USD 24.31 billion in 2025 and is projected to reach USD 48.27 billion by 2035, registering a compound annual growth rate (CAGR) of 7.1% during the forecast period (2026–2035). This growth trajectory is supported by increasing therapeutic applications, rising diagnosis rates of immune-related disorders, and expanding plasma collection infrastructure worldwide. The industry is also benefiting from ongoing investments in biologics manufacturing and fractionation technologies, which are improving scalability and efficiency.
Request Sample @ https://www.researchnester.com/sample-request-6099
Plasma Derived Therapy Industry Demand
Plasma derived therapies are medicinal products created from human plasma, a vital component of blood rich in proteins such as immunoglobulins, clotting factors, and albumin. These therapies are primarily used to treat patients with immune deficiencies, bleeding disorders, and other serious medical conditions.
Demand for plasma derived therapies is rising due to their proven clinical efficacy and versatility across multiple therapeutic areas. One of the key advantages is their cost-effectiveness over long-term treatment cycles, especially in chronic disease management. Additionally, these therapies are often designed for ease of administration, including intravenous and subcutaneous delivery formats, improving patient compliance.
Another important factor driving demand is their extended shelf life, which facilitates storage and distribution across regions with varying healthcare infrastructure. This is particularly valuable in emerging markets where cold chain logistics may be challenging. Furthermore, increasing awareness among healthcare providers and patients, combined with improved diagnostic capabilities, is expanding the eligible treatment population.
Plasma Derived Therapy Market: Growth Drivers & Key Restraint
Growth Drivers –
Rising Prevalence of Chronic and Rare Diseases
The increasing incidence of conditions such as hemophilia, primary immunodeficiency disorders, and autoimmune diseases is a major driver. As diagnostic techniques improve, more patients are being identified and treated, significantly boosting demand for plasma-derived therapies.
Technological Advancements in Plasma Fractionation
Innovations in plasma fractionation and purification processes are enhancing product safety, yield, and efficiency. Advanced technologies allow manufacturers to extract multiple therapeutic proteins from a single plasma unit, improving production economics and enabling higher output.
Expansion of Plasma Collection Networks and Outsourcing Trends
The growth of plasma collection centers, particularly in developed economies, is ensuring a stable supply of raw material. Additionally, outsourcing of plasma processing and contract manufacturing is becoming more prevalent, allowing companies to scale operations and reduce capital expenditure.
Restraint –
Despite strong demand, the market faces constraints related to plasma availability. Plasma collection is highly regulated and dependent on donor participation, which can fluctuate due to regulatory, ethical, or socio-economic factors. This supply-demand imbalance can limit production capacity and increase costs.
Plasma Derived Therapy Market: Segment Analysis
Segment Analysis by Product–
Immunoglobulin
Immunoglobulins represent the dominant segment due to their extensive use in treating immune deficiencies and autoimmune disorders. Demand is consistently strong, driven by expanding clinical indications and increasing off-label usage. Growth is supported by ongoing research into new therapeutic applications and improved formulations that allow subcutaneous administration.
Coagulation Factor
This segment plays a critical role in managing bleeding disorders such as hemophilia. Demand is stable and driven by lifelong treatment requirements for affected individuals. While recombinant alternatives exist, plasma-derived coagulation factors remain essential in certain patient populations, particularly where inhibitors or specific clinical needs are present.
Albumin
Albumin is widely used in critical care settings, including trauma, burns, and liver diseases. It benefits from broad clinical acceptance and versatility. Growth is fueled by increasing surgical procedures and rising demand in intensive care units, especially in developing healthcare systems.
Segment Analysis by Application –
Hemophilia
The hemophilia segment remains a key application area due to the necessity of continuous treatment. Plasma-derived therapies are crucial for patients who develop resistance to recombinant treatments. Demand is influenced by improved diagnosis rates and better access to treatment in emerging regions.
Primary Immunodeficiency Diseases (PID)
This segment is experiencing strong growth due to heightened awareness and early diagnosis. Plasma-derived immunoglobulins are the standard of care, and long-term therapy requirements ensure sustained demand. Increasing screening programs are further supporting market expansion.
Idiopathic/Immune Thrombocytopenic Purpura (ITP)
The use of immunoglobulins in ITP treatment is growing, particularly in acute care settings. Demand is driven by their rapid therapeutic effect in increasing platelet counts. The segment benefits from expanding clinical adoption and evolving treatment guidelines.
Plasma Derived Therapy Market: Regional Insights
North America
North America holds a leading position in the Plasma Derived Therapy Market, driven by a well-established healthcare system and robust plasma collection infrastructure. The region benefits from high awareness levels, advanced diagnostic capabilities, and strong reimbursement frameworks. The presence of major market players and continuous investment in research and development further support growth.
Europe
Europe represents a mature market with steady growth, supported by government healthcare initiatives and increasing demand for biologics. The region emphasizes stringent regulatory standards and quality control, which enhances product safety and patient trust. Growth is also driven by rising prevalence of chronic diseases and improved access to advanced therapies.
Asia-Pacific (APAC)
The Asia-Pacific region is emerging as a high-growth market due to expanding healthcare infrastructure and increasing patient population. Rising healthcare expenditure, growing awareness of rare diseases, and improving diagnostic capabilities are key demand drivers. Additionally, governments in several countries are investing in local plasma collection and fractionation facilities, reducing dependency on imports and boosting regional growth.
Top Players in the Plasma Derived Therapy Market
The Plasma Derived Therapy Market is highly competitive and consolidated, with key players focusing on expanding plasma collection networks, enhancing production capabilities, and investing in research and development. Major companies operating in this market include ADMA Biologics, Inc., Bio Products Laboratory Ltd., Biotest AG, Grifols, S.A., Kedrion S.p.A., Octapharma AG, Pfizer Inc., SK Plasma, and Kamada Pharmaceuticals, all of which play a crucial role in shaping the competitive landscape through product innovation, strategic partnerships, and global expansion initiatives.
Access Detailed Report @ https://www.researchnester.com/reports/plasma-derived-therapy-market/6099
Research Nester Analytics is a leading service provider for strategic market research and consulting. We provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates, and executives make informed decisions regarding future marketing strategy, expansion, and investments. We believe every business can expand its horizon with the right guidance at the right time. Our out-of-the-box thinking helps clients navigate future uncertainties and market dynamics.
Contact for more Info:
AJ Daniel
Email: info@researchnester.com
U.S. Phone: +1 646 586 9123
U.K. Phone: +44 203 608 5919
Comments (0)